The Lever, January 28, 2025: We are working with a consortium of experts to expose problems with FDA approvals. Our first article published in The Lever focuses on the clear risks and questionable benefits of drugs for early cognitive impairment caused by Alzheimer’s and how conflicts of interest resulted in approval.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
FDA webpages on clinical trial diversity removed after Trump orders
MedTechDive, January 27, 2025: FDA webpages on how to improve diversity in clinical trials and other topics were immediately removed after Trump was inaugurated and ordered numerous federal agencies to pause in communicating with the public. We explain that diversity in clinical trials is not affirmative action, it is needed to ensure that medical products are safe and effective for males and females and for people of all ages and races. The new FDA Commissioner hasn’t been confirmed, so who made these decisions?
Read More »In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways
STAT News, January 10, 2025: The FDA’s new guidance to Pharma on how to develop weight loss drugs reflects a cultural shift that treats drugs as the first resort instead of the last resort if changing eating habits and exercising doesn’t work.
Read More »Beyond Step Counting: Wearable Tech Promises Medical-grade Data
Barron’s, January 8, 2025: Barron’s article from AFP News describes the promise of new wearable medical devices for improving health and the criticisms by NCHR’s Diana Zuckerman and other experts regarding the lack of certainty about their accuracy due to low regulatory standards by the FDA. This makes it difficult to know which products are accurate and which ones aren’t.
Read More »FDA Off-Label Drug Guidance: 3 Things to Know
Law360, January 7, 2025: FDA Final Guidance on promoting off-label uses of approved drugs will increase sales but we explain it misleads doctors and patients about safety and efficacy because unapproved uses of drugs are not proven to be safe or effective.
Read More »